Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lessened its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) by 41.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 42,571 shares of the company’s stock after selling 29,619 shares during the quarter. Russell Investments Group Ltd. owned 0.09% of Prestige Consumer Healthcare worth $2,677,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Global Retirement Partners LLC lifted its holdings in shares of Prestige Consumer Healthcare by 3,435.7% during the third quarter. Global Retirement Partners LLC now owns 495 shares of the company’s stock worth $27,000 after purchasing an additional 481 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Prestige Consumer Healthcare by 38.1% during the third quarter. Versant Capital Management Inc now owns 587 shares of the company’s stock worth $29,000 after purchasing an additional 162 shares during the period. Ronald Blue Trust Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 68.9% during the fourth quarter. Ronald Blue Trust Inc. now owns 1,017 shares of the company’s stock worth $50,000 after purchasing an additional 415 shares during the period. Quadrant Capital Group LLC lifted its holdings in shares of Prestige Consumer Healthcare by 474.7% during the third quarter. Quadrant Capital Group LLC now owns 1,092 shares of the company’s stock worth $54,000 after purchasing an additional 902 shares during the period. Finally, Eagle Bay Advisors LLC lifted its holdings in shares of Prestige Consumer Healthcare by 116.7% during the fourth quarter. Eagle Bay Advisors LLC now owns 1,534 shares of the company’s stock worth $96,000 after purchasing an additional 826 shares during the period. Institutional investors and hedge funds own 99.98% of the company’s stock.

Prestige Consumer Healthcare Trading Up 0.7 %

Shares of PBH stock opened at $60.04 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.44 and a quick ratio of 1.43. The company has a market cap of $2.98 billion, a price-to-earnings ratio of -35.74, a PEG ratio of 1.72 and a beta of 0.56. The stock has a 50 day simple moving average of $61.42 and a 200-day simple moving average of $61.50. Prestige Consumer Healthcare Inc. has a 1-year low of $48.51 and a 1-year high of $67.45.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last announced its earnings results on Thursday, May 4th. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.03. The business had revenue of $285.90 million during the quarter, compared to the consensus estimate of $280.58 million. Prestige Consumer Healthcare had a positive return on equity of 13.38% and a negative net margin of 7.30%. The business’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.91 EPS. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on PBH shares. StockNews.com began coverage on Prestige Consumer Healthcare in a report on Thursday. They set a “buy” rating for the company. Royal Bank of Canada reduced their price target on Prestige Consumer Healthcare from $107.00 to $104.00 and set a “sector perform” rating for the company in a research report on Friday, March 17th. Oppenheimer reduced their price target on Prestige Consumer Healthcare from $72.00 to $71.00 and set an “outperform” rating for the company in a research report on Friday, February 17th. Finally, TheStreet cut Prestige Consumer Healthcare from a “b+” rating to a “c+” rating in a research report on Thursday, May 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $79.25.

Prestige Consumer Healthcare Company Profile

(Get Rating)

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.